Quality of life is an important attribute of antihypertensive therapy. Previous studies have not addressed the importance of a patient's prior pharmacotherapy on quality of life, which may serve as the basis of reference for a new therapy. Nor have previous studies compared commonly used quality of life instruments for consistency, or investigated whether improvement or worsening of quality of life correlates with adverse events or blood pressure reduction. Two hundred eighteen hypertensive patients with diastolic blood pressure (95 to 114 mm Hg) after a 4-to S-week placebo wrshe~f yerind were enrolled in a randomized double-blind, parallel group dose-escalation trial to compare the effects of amlodipine (2.5 to 10 mg), bisoprolol (2.5 to 10 mgllhydrochlorothiatide (HCTZ) 6.25, and enalaprtl (5 to 20 mg) on blood pressure, adverse events, and quality of life. Three quality of life instruments (General Well-Being Index, Vital Signs Qua!ity of Lifr, Zung Self-Rating Depression Scale) were administered during original therapy, after placebo washout, and after 12 weeks of optimally titrated clinical trial pharmacotherapy.
Our results demonstrated that removal from prior therapy had no detectable influence on subsequent evaluation of quality of life. The three quality of life instruments were consistent with the changes observed with the three therapies: a trend toward better quality of life with amlodipine and bisoprolol/HCTZ. Adverse events, but not systolic or diastolic blood pressure reduction correlated directly with changes in quality of life. Am J Hypertens signed for different clinical trials and various dcmclgraphic groups, but nn unified approach has heen devised for its measurement, and thrre IS somedisagree-:ncnt as to r\*hat quality of life really means."."' Mweovrr, investigators haye not studied.whether rcJuiing blond pressure, in and ol itself, mnv be impo;ta~,t for qunlitv of life, 1u.r has an cbfftlrt been made to corrrlatc drut;-related ndvl'rx* cvrnts Lvitlr chan);cas in a lwticnt's qualitv of lift. Nc) >tLldit*s haven addrcswd tvhcthcr or not prev~our wtihypertcnsivc therapy may influence a patient's basis of refrrww for evaluntmg new drug therapy.
The purpose of our clinical study was to address home of these questions, and hopefully Improve our undersc,lndmg about the intcrrelatlon~hip of blood pressure reductirw, adverse events, ,lnd pre\,ious treatment ther'tpy in comparmg quAt~ 01 htc tre,\t-mrnt chnnges \vlth different form3 of antlhypertensive therapies. A second aspect of our study ~vas ta compare single drug titration versus I~r~\~-dose niriltimechanism therapy titration on changes in quality ot lifr. Three diffrrcni previously validated instrum& ~ccrc t;sed to address diffcrcnzrs in quality of life responses by the participants, with the General IVeIlILsint; Index ser:,ing 2s t!?e +m.~rv mw+ure for quaIity of life determination.
METHODS

Study Population
The study population consisted of patients 21 years or older Lvith mild-to-mcxleratt esscnti?l hyyrtrnsion ta\wage sittm): diastohc blood prwslw.Y5 to II4 mm I+, inclusi\:e, at each of the last two visits of a ptacrho washtbut period ). Full written ctmwnt ~vas obtained f-cm z!! patients, and In\ostijia-tional Review Board approval was granted at zaclr sitca. I'qticnts wereexciuded for secondary hype+wion; slgnilicant rardioxxcular, hrpatic, or renal disease: nlcohol or drug abut; concomitant medications that mtlutnce blood pressure; any abnormalitv that may mtz:ferr with drug absorption; or contraindications to treatment with any of the study drugs. W.mwn ot childbearing potential practicing ,m effcyti\e method of bwth cnntro! wew allowed to participate.
Study Design This \vas a 17.lvtwk multic-cnter, nndomized, double-blind, parallel group tn.J comparing three strengths of amltdipinr b+ate (2.5,5, and 10 mg 1, biwprolol fumaratc / h~drc~hlorothia/Idr (HCT%j (23 I 6.25, S/6.25, and 10/h.25 mgj, and cn;tIapril maleatc (5, 10, and 20 mg) in the treatment ot patients with mild-tcb mtxlrratc hypertension. Patients satisfying the tligibllitj criteria lv'cre stratified by age and race a,!.! IX dumiztxi to one of three treatment group Lvithin wn','r~. .\I1 drugs were administercxi once daily in the mommg. To nAntam the double-blind design, active drugs were prep"r'cI II~ years. Thrre wrre no wgnificant dititwncw in baselirw dlastollc blood pressure or baseline heart rate among treatment groups;. There were differences in m:'an svstolic blood pressure and mean rveight 'It baselIne.
Effk~y
The mean dc:creases 111 systuhc and dxwtolic blood prrssurc from baseline we're 13.4 ; 10.7. 12.8 / 10.2, and 7.3 /h h mm 11): for the biwprolol/6.25 mg HCTZ, amlodipine, and cnalapril groups, rc>pectiveJ) The hypotcnsiw effects from bawline l\vere strongly significant (1' c: .nOl 1 for all thrcu drugs: however, the changes from baseline for both the svslolicand diastolic blood pressures of thr bisoprolol /b.25 mg IiCTZ and amlodipine groups were greater than 0 't change from baseline of the cnalapril group (P <: .Ol ). The mean drug dnsages wc'rc 5.7.6.7, and 13.9 mg for the bisoprolo1 ,ih.?i mg I-JCl Z, dmlo~lipine, and en,ilaprll groups, rcsp~~ctlvely.
The heart ralc Jecre~wtxJ by h. 
Quality of Life Analyses
To aiscs5 [r := 031, P .r .oCnll]).
With a view to determining whether there wtw at::, carryover cftccts of pwvious ther'?py, analy>cs were carried nut comparing quality of life scores with the GWBI at the time of s&eening versu3 ihow at thr end of placebo rut:-in. There wc'rc' no Ggniilcant changt5 in quality of life sc'nres lwt\vwn screwing on prior therapy and end of washout.
Changes in quality of lift for the various treatment groups are given in Table 2 . The bisoprolvl/6.25 mg HC'T(. and amlodipine groups consistently trended toward impnx~wicnt, ~vhcrcas the enalapril-treated pa- 
Thew observations dix-aunt prcviuus thwries that positive feelings may rnic~r~:c as d result of lo\+.wlng blood pressure rather than 4 +pcGhc actwn dthe nntihypertenslvr drugs."' It also Jmiinishes the Irypothesis that mild-to-moderate hvpertcnsron ma\ bc more of a sym~~tomatic' diw13(I than had b&n earllcr thought.
To determine whether the patient's previous thcrspy could influt nrc subseqwnt asscsrment of clualit! of life on new tker.lpy, \vr compared the C,WHI szorcs of the'patienta on their original therapy with their scores after 4 tab 5 weeks of placebo, anb then rompared those ch.rngrs with their scores after bring retested at the end of their new clinical trial therapy. WC could not iremonstratc any iniluence of prik)r trcatment or lack of prcvinus treatment im t!w patients' new trcatmcnt responws. Thus prcviw\ h~iwliw quality of litc does not appear to influcncv new tr<*.ltmcnt cvaluatmn. '1 his is an important obscxaiion AS it v,llidatca prior stud~cs Jcmc \vithout thi4 t)pc' of pretreatment assessment.
We used the GWHI, \'5QOl, and 7SKi)S tests 11) compare changes in quality of lift, \\.lth the three study therapies. Chvrall, the bisoprolnl ! 6.25 mg I K-T/. .~nd amlndipinr therapiexs were hcttcr tolt~ratcd than thr enalapril therapy Altht)ugh this directional impro\:emrnt did not achieve &xtistiral significance, it \va:, consistently obsen~ed with all three quality of life instruments. Althollgh previous quality of lift, ~SWW-ments have indicated, particularly with regard to sr'xual dystunctlon,'-,'C that high-dose thlazldes may worsen quality of life. A mow recent study demonstrates that lower doses are quite well tnlcrated.'"Our results are ct,nslstt:nt with these studies .lnd demonstrate that I,~xv--ilose thiazide diuretic (6 25 mg) in conjunction with a /j-blocker is as well tolerated as either a calcium rhannel blocker x an angiotensin convertine enzvme inhibitor. In Dart. the chnical sienificanw of our results &xv25 from our obscrvatlol:r. 3; a ecnrrai Iaik of'diifcrcncc between t!w 0irc.e difieren:
driig rcagimcns on quality of Me measures rather th,in Ggnitirant dificrcncrs bctwecn them. 4lorcover. there was consistency in our obwrvationk using three pre-\:i0uslv v.ilidatcd qwlitv of life instruments. Thcsc results are m concert rvith previous clinical studies that demonstrate no substantial or conqistcnt dlfterewes in qualit!-of life \vltil angi(\tznsin contrrtin): cnzvme inhibitor>, c.llc;um channel blockers, and o/Iblochcrs, other than propranolnl."' "
